5315-24-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
2-Methyl-6-hydrazinopyridine is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique chemical structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Corrosion Inhibition:
2-Methyl-6-hydrazinopyridine is used as a corrosion inhibitor in various industrial applications. Its ability to form complexes with metal ions helps protect metal surfaces from corrosion, extending the lifespan of equipment and reducing maintenance costs.
Used in Coordination Chemistry:
2-Methyl-6-hydrazinopyridine is used as a ligand in coordination chemistry. Its ability to form stable complexes with metal ions makes it a valuable tool for the study of metal ion interactions and the development of new coordination compounds with potential applications in various fields.
Used in Antitumor and Anticancer Research:
2-Methyl-6-hydrazinopyridine is used as a research compound in the field of antitumor and anticancer drug development. Its potential anti-tumor and anti-cancer properties have been studied extensively, and it may serve as a valuable tool in the discovery of new therapeutic agents for the treatment of cancer.
Used in Heterocyclic Compound Synthesis:
2-Methyl-6-hydrazinopyridine is used as a precursor to a range of heterocyclic compounds. Its unique structure allows for the synthesis of various heterocyclic compounds with potential applications in pharmaceuticals, agrochemicals, and other industries.

InChI:InChI=1/C6H9N3/c1-5-3-2-4-6(8-5)9-7/h2-4H,7H2,1H3,(H,8,9)

Upstream product

• 5315-25-3 2-bromo-6-methylpyridine 
• 407-22-7 2-fluoro-6-methylpyridine 
• 18368-63-3 6-chloro-2-picoline 
• 38557-71-0 2-chloro-6-methylpyrazine 

Downstream Products

• 957655-81-1 C₂₃H₁₈N₄O₂ 
• 723286-86-0 3-(trifluoromethyl)-5-methyl-[1,2,4]triazolo[4,3-a]pyrazine 
• 4926-18-5 5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 4926-14-1 5-methyl-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine 
• 96206-92-7 2-methyl-6-(phenylethynyl)pyridine 
• 5528-51-8 5-methyl-[1,2,4]triazolo[4,3-a]pyridine 
• 1427301-11-8 C₂₂H₁₆Cl₂F₃N₇ 
• 1431142-72-1 C₂₇H₂₄Cl₂F₃N₇O₂ 
• 701979-19-3 4-[1-(6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-1H-[1,2,4]triazol-3-yl]-benzonitrile 

Relevant academic research and scientific papers

TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and/or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and/or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-BETA R1 KINASE INHIBITOR

Disclosed are a group of 5-(4-pyridyloxy)pyrazole compounds serving as a TGF-βR1 kinase inhibitor, and applications of same in preparing a TGF-βR1 kinase inhibitor medicament. Specifically disclosed are the compounds as represented by formula (I), a pharm

Pyrazolo-cyclic compound, pharmaceutical composition containing pyrazolo-cyclic compound, and preparation method and application of pyrazolo-cyclic compound

The invention belongs to the field of medicinal chemistry, and relates to a pyrazolo-cyclic compound, a pharmaceutical composition containing the pyrazolo-cyclic compound, and a preparation method and application of the pyrazolo-cyclic compound. Specifica

ASK1 inhibitor and application thereof

The invention relates to compounds represented by a general formula (I) shown in the specification, a pharmaceutically acceptable salt and ester, or a stereoisomer of the compounds. The invention alsorelates to a preparation method of the compounds, a pharmaceutical preparation and a pharmaceutical composition containing the compounds. The compounds provided by the invention can effectively inhibit the amino acid phosphorylation of ASK1 and inhibit the activation of the ASK1; therefore, the compounds can treat and/or prevent ASK1-mediated diseases and related diseases.

Metal free [4+1] and [5+1] annulation reactions to prepare heterocycles using DMF and its derivatives as one-carbon source

1,2,4-Triazolo[3,4-a]pyridines and related heterocycles and substituted triazines were commonly discovered scaffolds in a variety of pharmaceutical and agrochemical agents. Herein, we report a highly efficient and practical method using DMF and its derivative for the [4+1] and [5+1] annulation reactions to prepare these heterocycles. This metal free reaction takes advantages of shelf stable DMF as solvent and carbon donor, imidazole chloride as a catalyst, the mild reaction condition tolerates a broad substrate range and substitutes. The prepared 3-unsubstituted 1,2,4-triazolo[3,4-a]pyridine and derivatives allow further introduction of a variety of functional group1 at 3-position.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

Exploring the unexplored practical and alternative synthesis of 3-(trifluoromethyl)-triazolopiperazine the key intermediate for Sitagliptin

The practical synthesis of 3-(trifluoromethyl)-triazolopiperazine the key intermediate of Sitagliptin and 3-(trifluoromethyl)-triazolopyridine was carried out employing industrially feasible transformations. The other advantage of this method is the new environment friendly approach to synthesize triazolopiperazine and triazolopyridines by eliminating the commonly used trifluoroacetic anhydride and polyphosphoric acid.

Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists

Previously disclosed C6 amido and benzimidazole dihydropyrazolopyrimidines were potent and selective blockers of IKur current. Syntheses and SAR for C6 triazolo and imidazo dihydropyrazolopyrimidines series are described. Trifluoromethylcyclohexyl N(1) triazole, compound 51, was identified as a potent and selective Kv1.5 inhibitor with an acceptable PK and liability profile.